A federal review board voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is non-mandatory. The FDA has given no signal on whether it will take up the recommendation. The move came after weeks of open hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could reshape how the agency handles a part of the wellness market that is growing very fast. Market observers are watching to see if the FDA picks up the plan. A representative for the regulator offered no clear schedule for a reaction. Wellness voices argue the change would widen access to substances users swear by. Critics warn that looser rules could invite misuse across a barely regulated market. The advisory vote only opens the door to a change, and the ultimate call rests with the federal agency.